Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008;83(6):898–903.
Article
PubMed
CAS
Google Scholar
Yeung CK, Shen DD, Thummel KE, Himmelfarb J. Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int. 2014;85(3):522–8.
Article
PubMed
CAS
Google Scholar
Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial. 2002;15(5):329–37.
Article
PubMed
Google Scholar
Kooman J, Dekker M, Usvyat LA, Kotanko P, van der Sande F, Schalkwijk CG, Shiels P, Stenvinkel P. Inflammation and premature aging in advanced chronic kidney disease. Am J Physiol Renal Physiol. 2017;313(4):F938–50.
Article
PubMed
Google Scholar
Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos. 2001;29(3):207–12.
PubMed
CAS
Google Scholar
Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434–8.
Article
PubMed
PubMed Central
CAS
Google Scholar
Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36(2):205–16.
Article
PubMed
CAS
Google Scholar
Harvey RD, Morgan ET. Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther. 2014;96(4):449–57.
Article
PubMed
CAS
Google Scholar
Burnier M, Pruijm M, Wuerzner G, Santschi V. Drug adherence in chronic kidney diseases and dialysis. Nephrol Dial Transpl. 2015;30(1):39–44.
Article
CAS
Google Scholar
Weir MR, Fink JC. Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease. Curr Opin Nephrol Hypertens. 2014;23(3):306–13.
Article
PubMed
CAS
Google Scholar
Ponticelli C, Sala G, Glassock RJ. Drug management in the elderly adult with chronic kidney disease: a review for the primary care physician. Mayo Clin Proc. 2015;90(5):633–45.
Article
PubMed
Google Scholar
Molanaei H, Stenvinkel P, Qureshi AR, Carrero JJ, Heimburger O, Lindholm B, et al. Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation. Eur J Clin Pharmacol. 2012;68(5):571–7.
Article
PubMed
CAS
Google Scholar
Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992;22(1):1–21.
Article
PubMed
CAS
Google Scholar
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270(1):414–23.
PubMed
CAS
Google Scholar
Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007;35(9):1687–93.
Article
PubMed
PubMed Central
CAS
Google Scholar
Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res. 2006;12(24):7492–7.
Article
PubMed
CAS
Google Scholar
Piafsky KM, Borga O, Odar-Cederlof I, Johansson C, Sjoqvist F. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. New Engl J Med. 1978;299(26):1435–9.
Article
PubMed
CAS
Google Scholar
Björkhem-Bergman L, Backstrom T, Nylen H, Ronquist-Nii Y, Bredberg E, Andersson TB, et al. Quinine compared to 4beta-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin. Drug Metab Pharmacokinet. 2014;29(4):352–5.
Article
PubMed
CAS
Google Scholar
Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome U, Einarsson C, et al. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem. 2001;276(42):38685–9.
Article
PubMed
CAS
Google Scholar
Diczfalusy U, Nylen H, Elander P, Bertilsson L. 4beta-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol. 2011;71(2):183–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Naud J, Nolin TD, Leblond FA, Pichette V. Current understanding of drug disposition in kidney disease. J Clin Pharm. 2012;52(1 Suppl):10S–22S.
Article
CAS
Google Scholar
Velenosi TJ, Urquhart BL. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin Drug Metab Toxicol. 2014;10(8):1131–43.
Article
PubMed
CAS
Google Scholar
Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757–73.
Article
PubMed
CAS
Google Scholar
Magnusson M, Magnusson KE, Sundqvist T, Denneberg T. Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut. 1991;32(7):754–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4(8):1065–74.
Article
PubMed
PubMed Central
CAS
Google Scholar
Steinman TI. Serum albumin: its significance in patients with ESRD. Semin Dial. 2000;13(6):404–8.
Article
PubMed
CAS
Google Scholar
Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089–96.
Article
PubMed
PubMed Central
Google Scholar
Baillie G, Mason N, editors. Dialysis of drugs: LLC, saline Michigan USA 2013.
Google Scholar
Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol. 2006;17(9):2363–7.
Article
PubMed
CAS
Google Scholar
Michaud J, Nolin TD, Naud J, Dani M, Lafrance JP, Leblond FA, et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharm Sci. 2008;108(2):157–63.
Article
CAS
Google Scholar
Coutant DE, Kulanthaivel P, Turner PK, Bell RL, Baldwin J, Wijayawardana SR, et al. Understanding disease-drug interactions in Cancer patients: implications for dosing within the therapeutic window. Clin Pharmacol Ther. 2015;98(1):76–86.
Article
PubMed
CAS
Google Scholar
Snaedal S, Heimburger O, Qureshi AR, Danielsson A, Wikstrom B, Fellstrom B, et al. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kid Dis. 2009;53(6):1024–33.
Article
PubMed
CAS
Google Scholar
Shah RR, Smith RL. Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clinical Pharm. 2015;79(2):222–40.
Article
Google Scholar
Shah RR, Smith RL. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos. 2015;43(3):400–10.
Article
PubMed
CAS
Google Scholar
Witasp A, Ryden M, Carrero JJ, Qureshi AR, Nordfors L, Naslund E, et al. Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. PLoS One. 2013;8(5):e63493.
Article
PubMed
PubMed Central
CAS
Google Scholar
Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Bottiger Y, Bertilsson L. 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clinical Pharm. 2009;67(1):38–43.
Article
CAS
Google Scholar
Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 “pie”. Drug Metab Dispos. 2006;34(5):880–6.
Article
PubMed
PubMed Central
CAS
Google Scholar
Yang J, Tucker GT, Rostami-Hodjegan A. Cytochrome P450 3A expression and activity in the human small intestine. Clin Pharmacol Ther. 2004;76(4):391.
Article
PubMed
CAS
Google Scholar
Galetin A, Gertz M, Houston JB. Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab Pharmacokinet. 2010;25(1):28–47.
Article
PubMed
CAS
Google Scholar
Basheer L, Kerem Z. Interactions between CYP3A4 and dietary polyphenols. Oxidative Med Cell Longev. 2015;2015:854015.
Article
CAS
Google Scholar
Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25(4):657–70.
Article
PubMed
CAS
Google Scholar
Bezirtzoglou EE. Intestinal cytochromes P450 regulating the intestinal microbiota and its probiotic profile. Microb Ecol Health Dis. 2012;23. https://doi.org/10.3402/mehd.v23i0.18370.
Diczfalusy U, Miura J, Roh HK, Mirghani RA, Sayi J, Larsson H, et al. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics. 2008;18(3):201–8.
Article
PubMed
CAS
Google Scholar
Björkhem-Bergman L, Bergstrom H, Johansson M, Parini P, Eriksson M, Rane A, et al. Atorvastatin treatment induces uptake and efflux transporters in human liver. Drug Metab Dispos. 2013;41(9):1610–5.
Article
PubMed
CAS
Google Scholar
Björkhem-Bergman L, Nylen H, Eriksson M, Parini P, Diczfalusy U. Effect of statin treatment on plasma 4beta-hydroxycholesterol concentrations. Basic Clin Pharmacol Toxicol. 2016;118(6):499–502.
Article
PubMed
CAS
Google Scholar
Perez GO, Hsia SL, Christakis G, Burr J. Serum cholesterol binding reserve and high density lipoprotein cholesterol in patients on maintenance hemodialysis. Horm Metab Res. 1980;12(9):449–54.
Article
PubMed
CAS
Google Scholar
Molanaei H, Qureshi AR, Heimbürger O, Lindholm L, Diczfalusy U, Anderstam B, et al. Inflammation down regulates cytochrome P450 mediated drug metabolism in hemodialysis patients. Nephrol Dial Transpl. 2016;i561:31.
Google Scholar